Search the Newsreel

What's Going On With Neurocrine Biosciences Stock On Wednesday?

Neurocrine Biosciences stock experienced a dip after reports emerged of deaths and severe complications potentially linked to its drug Vykat XR, used for Prader-Willi syndrome. The FDA's adverse event data revealed seven deaths and over 100 serious events, primarily involving edema, respiratory, and cardiac …

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace (NPCE) reported strong second-quarter 2026 results, with earnings and revenues surpassing Zacks Consensus Estimates, driven by significant growth in its RNS System. The company also raised its full-year 2026 revenue guidance and improved its adjusted EBITDA loss outlook. NeuroPace highlighted advancements in AI-based …

Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug

Reports have emerged of seven deaths and 100 serious adverse events potentially linked to Neurocrine Biosciences’ Prader-Willi syndrome drug, Vykat, prompting concerns among clinicians and patient advocacy groups. Concurrently, Aardvark Therapeutics terminated its Phase 3 trial for ARD-101 for the same condition due to …

Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug

Experts in Prader-Willi Syndrome have raised safety concerns regarding Neurocrine's drug Vykat XR, citing serious adverse events reported in patients. Post-marketing surveillance revealed reports of edema, respiratory and cardiac complications, and seven deaths linked to the drug as of July 31st, though no causal …

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

Neurocrine Biosciences announced the publication of KINECT-PRO™ Phase 4 study results, showing that INGREZZA® (valbenazine) capsules significantly improved patient-reported quality of life and daily functioning, alongside clinician-rated tardive dyskinesia (TD) movement severity. These improvements were seen across various patient demographics, including those with mild …

HC Wainwright Issues Pessimistic Forecast for Neurogene (NASDAQ:NGNE) Stock Price

Neurocrine slips on safety issues linked to Vykat XR (NBIX:NASDAQ)

Neurocrine Biosciences' shares fell following resurfacing safety concerns related to Vykat XR, a rare disease therapy acquired through Soleno Therapeutics. Reports of potential fatalities and severe side effects, such as edema, have been linked to the drug, though a definitive causal link has not …

HC Wainwright Has Bearish Estimate for NERV Q3 Earnings

HC Wainwright has revised its Q3 2026 EPS estimate for Minerva Neurosciences (NASDAQ:NERV) to a loss of $0.14 per share, a significant reduction from its previous forecast of a $0.01 loss. The firm also projects a $0.50-per-share loss for the full fiscal year 2026, …

Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say

A group of physicians and experts in Prader-Willi syndrome has notified clinicians about a series of patient deaths and severe side effects potentially linked to Neurocrine Biosciences' newly approved drug, Vykat XR. Approved in March 2025, Vykat XR is intended to manage intense hunger …

Alto Neuroscience Reports Q2 Loss As ALTO-207 Program Expands

Alto Neuroscience (ANRO) reported a net loss of $27.6 million for Q2 2026, an increase from $17.7 million a year prior, while also announcing the expansion of its ALTO-207 program with plans for an additional Phase 3 trial in treatment-resistant depression. The company secured …

Alto Neuroscience (ANRO) Earnings Date and Reports 2026

Trading the Move, Not the Narrative: (NEU) Edition

This article provides a detailed analysis of Newmarket Corp (NYSE: NEU), focusing on quantitative trading strategies rather than market narratives. It highlights strong near and mid-term sentiment, identifies no remaining resistance levels, and offers specific long, breakout, and short trading strategies generated by AI …

Price-Driven Insight from (NBXG) for Rule-Based Strategy

This article provides a price-driven analysis of Neuberger Berman Next Generation Connectivity Fund Inc. (NASDAQ: NBXG) for rule-based strategies. It highlights a near-term strong sentiment with a mid-channel oscillation pattern, offering a significant risk-reward setup. The analysis includes AI-generated institutional trading strategies tailored for …

Neuronetics (STIM) Stock Repriced After Margin Gains And EBITDA Breakeven

Form 8K Neuronetics Inc For: 11 August By Investing.com

This article reports on Neuronetics Inc.'s Form 8K filing for August 11, without providing further details on the content of the filing. It is a brief announcement from Investing.com, typical of financial news outlets reporting SEC filings. The piece primarily serves as a placeholder …

NeuroPace Q2 2026 slides: 21% RNS growth, $55B+ market opportunity

NeuroPace reported strong Q2 2026 results with 21.3% year-over-year revenue growth in its RNS System business, driven by increasing adoption in the adult focal epilepsy market. Despite beating analyst estimates, shares declined due to ongoing losses and regulatory uncertainty surrounding its idiopathic generalized epilepsy …

NeuroPace Raises FY26 Sales Guidance Above Estimates

NeuroPace Inc. has increased its sales guidance for fiscal year 2026 to $99.5 million-$101.5 million, surpassing the consensus estimate of $99.913 million. This upward revision indicates strong demand for its RNS System and improved visibility into recurring revenue, demonstrating the company's confidence in its …

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NeuroPace, Inc. reported its second-quarter 2026 financial results, with total revenue reaching $22.8 million and RNS revenue growing 21% to $22.5 million. The company raised its full-year 2026 total revenue guidance to $99.5 million to $101.5 million and improved its Adjusted EBITDA loss. NeuroPace …

NeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Earnings call transcript: NeuroPace tops Q2 2026 estimates, shares slip after hours

NeuroPace reported Q2 2026 results that exceeded Wall Street expectations for both earnings and revenue, but its shares fell in after-hours trading. The company posted a narrower adjusted loss and 17% revenue growth, driven by strong RNS System sales. Management raised full-year revenue and …

Neuropace earnings beat by $0.03, revenue topped estimates

NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates

NeuroPace, Inc. (NPCE) reported a Q2 loss of $0.18 per share, exceeding the Zacks Consensus Estimate of a $0.19 loss and showing an improvement from a $0.26 loss a year ago. The company also surpassed revenue estimates, posting $22.83 million against a consensus of …

Neuronetics (STIM) grows sales as going concern risk emerges under debt covenants

Neuronetics Inc. reported increased revenues for Q2 and H1 2026, primarily driven by its Greenbrook segment, and narrowed its net loss. However, the company flagged substantial doubt about its ability to continue as a going concern due to a projected failure to meet a …

NeuroPace Inc 2Q 2026: Revenue $22.8M, Net loss $(6.2M), EPS $(0.18) — 10-Q Summary

NeuroPace Inc reported its second-quarter 2026 results, showing a revenue of $22.8 million, a 17% increase year-over-year. The company posted a net loss attributable to common stockholders of $(6.2) million, with a diluted loss per share of $(0.18), an improvement from $(0.26) in the …

NeuroPace Inc.: Q2 Earnings Snapshot

Neumora Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Neumora Therapeutics Inc is projected to report an earnings loss of 24 cents per share. This information is provided as an earnings preview.

H.C. Wainwright Maintains Minerva Neurosciences(NERV.US) With Hold Rating, Maintains Target Price $7

H.C. Wainwright has reiterated its Hold rating for Minerva Neurosciences (NERV.US) and maintained a target price of $7. This indicates the firm's continued neutral outlook on the company's stock performance.

Neuronetics outlines 2026 revenue of $160M-$164M while shifting NeuroStar to broader ownership models

Earnings Call Insights: Neuronetics (STIM) Q2 2026 MANAGEMENT VIEW * "I'm pleased to report the second quarter began to reflect our steady execution against the goals I cited last quarter. Total revenue was $41.6 million, up approximately 9% versus the second quarter of last …

Neuronetics Q2 Earnings Call Highlights

Key Points Interested in Neuronetics, Inc.? Here are five stocks we like better. Q2 results improved significantly: Revenue rose 9.1% year over year to $41.6 million, while the net loss narrowed to $3.4 million and adjusted EBITDA turned positive at $0.3 million. Greenbrook was …

If You Invested $1,000 in WaveDancer, Inc. (WAVD)

This article analyzes the historical performance of a $1,000 investment in WaveDancer, Inc. (WAVD) over different periods, providing details on its annual returns and cumulative growth. It also explains WaveDancer's significant transformation from an IT services company to a medical technology and AI company …

Neurogene Q2 Results: EPS widens to $(1.53), misses estimates

Neurogene (NASDAQ:NGNE) Stock Price Down 7.8% on Disappointing Earnings

Neurogene (NASDAQ:NGNE) Posts Earnings Results, Misses Expectations By $0.11 EPS

Neuronetics (NASDAQ:STIM) Announces Earnings Results

Earnings call transcript: Neuronetics tops Q2 2026 forecasts as stock jumps 23%

Neuronetics publishes investor presentation on NeuroStar TMS, Greenbrook clinic network strategy

Neuronetics has released an investor presentation detailing its NeuroStar TMS and Greenbrook clinic network strategy. The company provided FY 2026 revenue guidance of $160 million to $164 million, projecting 7% to 10% year-on-year growth, alongside a gross margin outlook of 48% to 50%. It …